Drug Approval | April 26, 2022
Corbevax gets DCGI nod for Emergency Use in 5-12 years
The approval comes soon after Corbevax was given the nod for 12-15-year group
The approval comes soon after Corbevax was given the nod for 12-15-year group
Covaxin was earlier approved for children 12-18 years of age
This is the first major brand refresh of CanSinoBIO since its inception in 2009
April 25th is commemorated as World Malaria Day
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
Within a fortnight, over 200 contestants sent their entries for the competition, and 30 names were shortlisted after screening entries under different categories
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
The business is a recognized leader in managing Covid-19 and mRNA research programs
Subscribe To Our Newsletter & Stay Updated
